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Abstract
Background: Systemic sclerosis (SSc) is a disorder characterized by immune system alterations, vasculopathy and fibrosis.
SSc-related interstitial lung disease (ILD) represents a common and early complication, being the leading cause of mortality.
Monocytes/macrophages seem to have a key role in SSc-related ILD. Interestingly, the classically (M1) and alternatively (M2)
activated monocyte/macrophage phenotype categorization is currently under revision.
Our aim was to evaluate if circulating monocyte/macrophage phenotype could be used as biomarker for lung involvement
in SSc. To this purpose we developed a wide phenotype characterization of circulating monocyte/macrophage subsets in
SSc patients and we evaluated possible relations with lung involvement parameter values.
Methods: A single centre cross-sectional study was performed in fifty-five consecutive SSc patients, during the year 2017.
All clinical and instrumental tests requested for SSc follow up and in particular, lung computed tomography (CT) scan,
pulmonary function tests (PFTs), Doppler echocardiography with systolic pulmonary artery pressure (sPAP) measurement,
blood pro-hormone of brain natriuretic peptide (pro-BNP) evaluation, were performed in each patient in a maximum one-
month period. Flow cytometry characterization of circulating cells belonging to the monocyte/macrophage lineage was
performed using specific M1 (CD80, CD86, TLR2 and TLR4) and M2 surface markers (CD204, CD163 and CD206). Non-
parametric tests were used for statistical analysis.
Results: A higher percentage of circulating CD204+CD163+CD206+TLR4+CD80+CD86+ and CD14+CD206+CD163+CD
204+TLR4+CD80+CD86+ mixed M1/M2 monocyte/macrophage subsets, was identified to characterize patients affected
by SSc-related ILD and higher systolic pulmonary artery pressure. Mixed M1/M2 monocyte/macrophage subset showed
higher percentages in patients positive for anti-topoisomerase antibody, a known lung involvement predictor.
Conclusions: The present study shows for the first time, through a wide flow cytometry surface marker analysis, that
higher circulating mixed M1/M2 monocyte/macrophage cell percentages are associated with ILD, sPAP and anti-
topoisomerase antibody positivity in SSc, opening the path for research on their possible role as pathogenic or
biomarker elements for SSc lung involvement.
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Background
Systemic sclerosis (SSc) is a rare autoimmune dis-
ease, characterized by progressive microvascular
damage and fibrosis, involving almost all organs of
affected patients and predictable by several bio-
markers [1].
Interstitial lung disease (ILD) is a common and early
complication in SSc patients, and a certain degree of
ILD, in the form of non-specific interstitial pneumonia
(NSIP), has been shown in 78% of SSc lung biopsies.
Notably, among possible organ involvements in SSc, ILD
evolves to the worse prognosis, being the leading cause
of mortality in SSc patients [2].
In addition, patients affected by SSc-associated ILD have
a high risk to develop cardiopulmonary disease and pul-
monary hypertension. After pulmonary hypertension de-
velopment, severe impairments in both physical and
emotional domains of health-related quality of life were
demonstrated [3]. The 3-year death rate in SSc patients af-
fected by pulmonary hypertension was calculated to be
44–64% [4, 5].
SSc-associated ILD was demonstrated to be early rec-
ognized by lung computed tomography (CT) scan. On
the other hand, the wide range of pulmonary function
test (PFT) normal values (80–120% of predicted) may
determine its reduced sensitivity [6].
Several studies recently highlighted the genetic and epi-
genetic aberrations involved in the SSc pathogenesis [7, 8].
Importantly, major gene signatures related to phenotype,
activation and migration of macrophages demonstrated to
be relevant to the progressive pulmonary fibrosis, indicat-
ing macrophages as key players [9, 10].
Intriguingly, imbalance in macrophage phenotype features
and macrophage activation have been lately considered es-
sential for the development of inflammatory-autoimmune,
fibrotic, infective and neoplastic disorders characterized by
lung involvement [11–16]. Macrophages have been initially
categorized as classically (M1) or alternatively activated
(M2), mirroring T cells categories. M1 macrophages express
specific phenotype markers, including toll-like receptors
(i.e., TLR2 and TLR4) and the co-stimulatory molecules
CD80 and CD86, and are involved in triggering intensive in-
flammation and tissue damage [17]. M2 macrophages pri-
marily express the mannose receptor-1 (CD206) and
macrophage scavenger receptors (CD204 and CD163), and
they are associated with T helper (Th) 2 response, tissue re-
pair and fibrosis [18, 19].
Recently, classifications based on a wider spectrum of
phenotypes of which M1 and M2 subsets would consti-
tute the two extremes have been described [20].
Moreover, it was observed that the majority of alveolar
macrophages combine M1 and M2 features in steady
state and that the mixed M1/M2 phenotype can be al-
tered by HIV infection [21].
Interestingly, a recent preliminary study demonstrated
higher percentages of circulating mixed M1/M2 mono-
cytes/macrophages in SSc patients compared to healthy
subjects (HSs) [22]. The aim of the present study was to
effectuate a wide phenotype characterization of circulat-
ing monocytes/macrophages in consecutive SSc patients
stratified according to the severity of lung and right
heart involvement, through lung CT scan imaging, PFTs,
pro-BNP blood values, and Doppler echocardiography.
Methods
Study design
As part of the regular follow up approved by international
guidelines for SSc, all patients underwent clinical examin-
ation and instrumental exams over a period of time of up
to one month. In particular, lung CT scan, PFT with dif-
fusing capacity of the lungs for carbon monoxide (DLCO),
Doppler echocardiography with systolic pulmonary artery
pressure (sPAP) measurement, pro-hormone of brain
natriuretic peptide (pro-BNP) blood values, were per-
formed for lung-right heart involvement evaluation. The
assumption of medications was also considered.
The study was approved by the Ethics Committee of
Polyclinic San Martino Hospital, Genoa, Italy (protocol
number: 273-reg-2015).
Throughout the manuscript, the investigated cells were
defined as circulating “monocytes/macrophages”. This is
because we wanted to use as much surface markers as
possible, including those expressed from mature and po-
larized macrophages, to better restrict the investigation to
monocytes and macrophages, and to study the mixed M1/
M2 phenotype, independently from the cell maturation
state. In fact, we did not want to exclude also a possible
presence of circulating cells in later maturation stages.
Therefore, we used different gating strategies, as reported
in Additional file 1, including typical markers of immature
and mature cells, as previously described [22].
Participants
Fifty-five consecutive SSc patients (50 females and 5
males, mean age 63 ± 13 years), undergoing complete
disease staging in a day hospital setting at the Rheuma-
tology Division of Genoa University, were enrolled in
the study after written informed consent. Among the en-
rolled SSc patients, 36 were characterized by a limited
cutaneous (lcSSc) disease form and 19 were character-
ized by a diffused cutaneous (dcSSc) disease form. SSc
diagnosis was done according to the American College
of Rheumatology (ACR)/European League Against
Rheumatism (EULAR) 2013 criteria [23, 24].
Data from blood samples derived from a population of
27 sex and gender matched HSs, analysed in a recent
preliminary study, were applied here for comparison
with SSc patients, for the most significant results [22].
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Lung and right heart involvement parameters
Lung CT scan, PFTs and sPAP, pro-BNP value measure-
ments were performed in each patient in the same
period of the other examinations scheduled for SSc
follow-up. Results were interpreted by the same operator
for each type of diagnostic test.
Afterwards, patients were stratified according to the
presence or the absence of any interstitial involvement at
lung CT scan (SSc-ILD group versus SSc No-ILD group,
respectively). Therefore, patients were stratified also ac-
cording to the presence or the absence of single CT scan
abnormalities, characteristically described in SSc lung in-
volvement: ground glass opacities (defined as an area of
increased attenuation in the absence of architectural dis-
tortion) of lower lobes, ground glass opacities of upper
lobes, peripheral septal thickening, apical fibrotic (archi-
tectural distortion with reticular intra-lobular interstitial
thickening) changes, diffused fibrotic changes, traction
bronchiectasis and bronchiolectasis (dilatation of the air-
ways in the peripheral portion of the lung) and enlarged
mediastinal nodes [25].
As regards PFT, forced vital capacity (FVC), DLCO and
FVC/DLCO ratio values were reported and analyzed for
each SSc patient. In agreement with previous studies, the
FVC/DLCO ratio higher than 1.5 was considered suggest-
ive for pulmonary vasculopathy in SSc patients [26].
Flow cytometry
After enrolment, peripheral blood was collected in a
lithium-heparin single tube from each SSc patient.
To identify monocyte/macrophage lineage surface
markers CD14-APC-Vio770 and CD45-VioGreen anti-
bodies were used. The characterization of M2 phenotype
was performed using CD204-PE, CD163-PE-Vio770 and
CD206-PeerCP-Vio700, whereas the M1 phenotype was
investigated using CD80-APC, CD86-VioBlue, TLR2-PE-
Vio615 and TLR4-VioBright-FITC antibodies. CD66b
-FITC was used to identify and exclude granulocytes
(Miltenyi Biothech, Bergisch Gladbach, Germany).
A total of 0.1 ml of peripheral blood was incubated
with 10 μl of antibody for 15 min at room temperature,
then erythrocytes were lysed and leucocytes post-fixed.
Afterwards, the flow cytometry analysis was performed.
Three initial gating strategies were implemented to in-
vestigate circulating monocyte/macrophage phenotype
over total leucocyte population and included in the Add-
itional file 1. The first initial gating strategy evaluated
the CD14+ cells over total leucocyte population. In this
CD14+ cell population, circulating monocytes/macro-
phages showing an M2 phenotype were characterized
based on the expression of CD204, CD163 and CD206.
Therefore, a second initial gating strategy evaluated the
CD204+ cells in the leucocyte population, excluding lym-
phocytes, CD66b+ granulocytes, doublets and cellular
debris. In the CD204+ population, circulating cells
co-expressing CD163 and CD206 were detected to
characterize monocytes/macrophages showing an M2
phenotype. Cells positive for M2 phenotype markers
(CD204, CD163, CD206) and M1 phenotype markers
(TLR4, CD80 and CD86) were investigated to identify
the presence of cells with a mixed M1/M2 phenotype, as
recently reported [22]. Although lymphocytes and neu-
trophils are excluded in the initial gating strategy start-
ing from CD204 + cells, no specific dendritic cell markers
were investigated to discriminate these cells and then
they might be probably present in a limited percentage
in the M1/M2 mixed population.
Finally, a third initial gating strategy was made up to
detect monocytes/macrophages showing prominently
M1 surface markers CD80, CD86, TLR2 and TLR4 [27].
Flow cytometric analysis was performed using a
Navios Flow Cytometer and the Kaluza analysis software
(Beckman Coulter, Milan, Italy), evaluating a total of 5 ×
106 cells and detecting more than 30 events in the smal-
lest subset investigated, according to consensus guide-
lines on the minimal residual disease [28].
Statistical analysis
Data were analyzed using IBM SPSS Statistics Version
21.0. (IBM Corp: Armonk, NY). Non-parametric tests
were applied for statistical analysis and in particular
Mann-Whitney U test was used for comparing data with
an ordinal distribution between two independent groups.
Kruskal-Wallis test was chosen to assess significantly dif-
ferent distributions of continuous dependent variables by
a categorical independent variable with more than two
groups. Finally, bivariate Pearson’s correlation was calcu-
lated to measure linear relationship between two variables
with ordinal distribution. A p-value lower than 0.05 was
considered as statistically significant. The results were
expressed as median ± standard deviation (SD) and graph-
ically represented through box and whisker plots.
Results
Demographics and clinical parameters are summarized
in Table 1.
Only 5 males were enrolled among the SSc patient
population, consequently the sex variable was not used
for the analysis.
Associations between auto-antibody positivity, pro-BNP
blood values, disease form, and monocyte/macrophage
phenotype
Anti-topoisomerase antibody (Anti-Scl70) positivity was
associated with lower FVC% (Scl70 + = 84.5 ± 14% vs.
Scl70- = 112.8 ± 22; p < 0.0001) and higher pro-BNP
values (Scl70+ = 790 ± 883 vs. Scl 70- = 213 ± 243 p =
0.01) (Fig. 1a and b).
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In the circulating CD204+ cell population of Scl70
positive SSc patients, by Mann-Whitney test, several mixed
M1/M2 macrophage subsets showed higher percentages
compared to Scl70 negative SSc patients: CD204+CD163
+CD206+TLR4+CD14− cells (Scl70+ = 2.4 ± 4.6%, vs. Scl70-
= 0.64 ± 7.9%, p = 0.036), CD204+CD163+CD206+TLR4
+CD80+ cells (Scl70+ = 8.2 ± 8.2% vs. Scl70- = 0.86 ± 4.4%, p
= 0.027, Fig. 1e), CD204+CD163+CD206+TLR4+CD86+ cells
(Scl70+ = 2.2 ± 6.9% vs. Scl70- = 0.7 ± 3.6%, p = 0.046),
CD204+CD163+CD206+TLR4+CD80+CD86+ cells
(Scl70+ = 1.6 ± 6.7% vs. Scl70- = 0.54 ± 3.6%, p = 0.036,
Fig. 1c, d, f ).
Using HS data, as reported in the Methods section,
Kruskal-Wallis test was performed and significantly lower
percentages for the same cell populations in HSs were ob-
tained (HSs values for CD204+CD163+CD206+TLR4+CD14−
cells = 0.17 ± 0.41%, p < 0.0001 vs. SSc patients, pairwise
comparison: HSs vs Scl70- p= 0.05, HSs vs Scl70+ p <
0.0001; CD204+CD163+CD206+TLR4+CD80+ cells = 0.16 ±
0.48%, p < 0.0001 vs. SSc patients, pairwise comparison: HSs
vs Scl70- p= 0.001, HSs vs Scl70+ p < 0.0001;
CD204+CD163+CD206+TLR4+CD86+ cells = 0.18 ± 0.36%, p
< 0.0001 SSc patients, pairwise comparison: HSs vs Scl70- p
= 0.001, HSs vs Scl70+ p < 0.0001; CD204+CD163
+CD206+TLR4+CD80+CD86+ cells = 0.08 ± 0.29%, p < 0.0001
SSc patients, pairwise comparison: HSs vs Scl70- p= 0.001,
HSs vs Scl70+ p < 0.0001, Additional file 2).
No association was reported between Scl70 Ab positiv-
ity and cells expressing exclusively M1 or M2 phenotype
markers.
Anti-centromere antibodies (ACA) positivity was asso-
ciated with older age at the time of the study (ACA+ =
70 ± 7 vs. ACA- = 57 ± 14 years, p = 0.002), longer SSc
duration (ACA + = 10 ± 6 vs. ACA- = 7 ± 6 years, p =
0.049), higher FVC percentage (ACA+ = 118 ± 19% vs.
ACA- = 94 ± 21%, p < 0.0001), and lower gammaglobulin
percentage values (ACA+ = 14.8 ± 3% vs. ACA- = 17.3 ±
3%, p = 0.004).
ACA positive patients showed a higher percentage of
CD14+ cells (ACA+ = 7.3 ± 1.9% vs. ACA- 6.3 ± 2.4%, p
= 0.022). Several cells more clearly polarized towards an
M1 or M2 phenotype segregated with ACA positivity:
CD14+TLR2+ (ACA+ = 7.2 ± 2.6% vs. ACA- = 6 ± 3%, p
= 0.046), CD14+CD163+ (ACA+ = 7 ± 1.9% vs. ACA- =
5.8 ± 2.6%, p = 0.025), and CD14+CD204+CD163+ (ACA
+ = 0.18 ± 0.4% vs. ACA- = 0.08 ± 0.3%, p = 0.011).
Only CD204+CD163+CD206+TLR4+CD80+ cells, in
the circulating CD204+ cells, showed higher percentages
in dcSSc compared to lcSSc patients (dcSSc = 2.96 ± 8%
vs. lcSSc = 0.94 ± 5%, p = 0.047). The Kruskal-Wallis test,
executed adding HSs data, showed significantly lower
CD204+CD163+CD206+TLR4+CD80+ cell percentages in
comparison to both lcSSc and dcSSc (0.16 ± 0.48%, p <
0.0001, globally and after pairwise comparison).
Associations between lung disease evaluated at CT scan
and monocyte/macrophage phenotype
The only gating strategy that effectively highlighted
differences in circulating monocyte/macrophage
phenotype between SSc-ILD versus SSc-No ILD
group was the one based on initial gating of CD204+
cells (Table 2).
No significant difference was reported for total
CD204+ cell percentage, over circulating leukocytes, be-
tween SSc-ILD patient and SSc-No ILD patient groups
(Table 2).
Table 1 Demographic clinical and imaging data from the
whole systemic sclerosis patient population
Demographic, clinical and
imaging data in SSc PTs
Mean ± SD OR
number-percentage
Age (years, mean ± SD) 63 ± 13
Sex (females/males) 50/5
RP duration (years, mean ± SD) 5.8 ± 10
SSc duration (years, mean ± SD) 8.4 ± 6
SSc form = LcSSc/dcSSc (n =%) 36 = 65.5% /
19 = 34.5%
ANA (n =%) 55 = 100%
ACA (n =%) 20 = 36.4%
Anti-Scl-70 Ab (n =%) 23 = 41.8%
ILD at CT scan (n = %) 37 = 67.3%
Ground glass opacities, lower lobes (n =%) 13 = 23.6%
Ground glass opacities, upper lobes (n =%) 8 = 14.5%
Ground glass opacities, upper and lower
lobes (n =%)
8 = 14.5%
Peripheral septal thickening (n =%) 31 = 56.4%
Apical fibrotic changes (n =%) 20 = 36.4%
Diffused fibrotic changes (n =%) 15 = 27.3%
Enlarged mediastinal nodes (n = %) 16 = 29.1%
Traction bronchiectasis and bronchiolectasis
(n = %)
16 = 29.1%
FVC% (mean ± SD) 104 ± 24
DLCO/VA% (mean ± SD) 71.5 ± 20
sPAP mmHg (mean ± SD) 34 ± 7
Pro-BNP (pg/ml, mean ± SD) 1423 ± 5119
On immunosuppressive therapy (n = %) 32 = 56.1%
On glucocorticoids (n =%) 9 = 16.4%
On ERAs (n =%) 16 = 28.1%
Data are expressed as means ±standard deviations or numbers = percentages
of the total population. SSc Systemic sclerosis, PTs patients, RP Raynaud’s
phenomenon, SD standard deviation, ILD interstitial lung disease, ANA
Anti-nuclear antibody, ACA: Anti-centromere antibodies, Ab anti-Scl70
anti-topoisomerase antibody, CT computed tomography, FVC forced vital
capacity, DLCO diffusing capacity of the lungs for carbon monoxide, sPAP
systolic pulmonary artery pressure, pro-BNP prohormone of brain natriuretic
peptide, ERAs Endothelin 1 receptor antagonists. No other vasomodulating
therapies were used by the selected SSc patients
Trombetta et al. Respiratory Research  (2018) 19:186 Page 4 of 12
Considering the CD204+ cell population, SSc-ILD pa-
tients showed a significant increased percentage of circulat-
ing CD204+CD163+ cells compared to SSc-No ILD patients
(Table 2). Likewise, circulating CD204+CD163+TLR4+ cells,
CD204+CD163+CD206+TLR4+ cells, showed significant
higher percentages in the SSc-ILD group (Table 2). Among
CD204+CD163+TLR4+CD206+ cells, only CD14− and not
CD14+ cells showed significantly higher percentages in the
SSc-ILD group (Table 2).
Remarkably, in the CD204+CD163+CD206+TLR4+ cell
population, mixed M1/M2 phenotype cells expressing
CD80 and CD86 markers resulted significantly increased in
the SSc-ILD group compared to the SSc-No ILD group
(Fig. 2 a, b, c, d and Table 2).
No differences were observed between SSc-ILD and
SSc-No ILD patients in the percentage of total circulat-
ing CD14+ cells (6.68 ± 1.8% and 7.57 ± 2.5%, respect-
ively, p = 0.18).
Fig. 1 Ab anti Scl70 positivity: associations with FVC%, Pro-BNP blood values and mixed M1/M2 cells percentages. a and b, clinical associations of Anti-
Scl70 Ab positivity with lower FVC% and higher pro-BNP values are shown. c and d show the representative dot plots from the flow cytometry analysis
of the mixed M1/M2 CD204+CD163+CD206+TLR4+CD80+CD86+ cell subset is shown in patients with positive and negative Ab anti-Scl70. Significant
differences (p = 0.027) are shown between average percentages of circulating mixed M1/M2 subset CD204+CD163+CD206+TLR4+CD80+ over total
CD204+ cells, in Scl70+ vs Scl70- patients (e) and between percentage of circulating mixed M1/M2 subset CD204+CD163+CD206+TLR4+CD80+CD86+
over total CD204+ cells, in Scl70+ vs Scl70- patients (f). Anti-Scl70 = Anti-topoisomerase; FVC = forced vital capacity; pro-BNP = prohormone of brain
natriuretic peptide
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No differences were observed between SSc-ILD and
SSc-No ILD patients in the percentage of circulating
monocytes/macrophages expressing only surface markers
considered to be M1 specific.
Monocytes/macrophages phenotype and single CT scan
alterations associated with interstitial lung disease, in SSc
patients
Interestingly, SSc patients showing fibrotic changes dif-
fused to upper and lower lobes at lung CT scan, seemed
to be characterized by a slightly higher percentage of
mixed M1/M2 monocytes/macrophages and character-
ized as CD14+CD206+CD163+CD80+CD86+ compared
to patients with less or no lung fibrosis (0.001 ± 0.008
and 0.0006 ± 0.006, p = 0.044). Coherently, the same cell
population showed higher percentages in patients pre-
senting bronchiectasis or bronchiolectasis (0.002 ±
0.008% and 0.0006 ± 0.006%, p = 0.021).
No significant difference was reported in circulating
monocyte/macrophage phenotype between patients with
reported ground glass opacities localized at lower or
upper lung lobes or diffused to both locations at lung
CT scan. Similarly, no significant difference was ob-
served in SSc patients for whom peripheral septal thick-
ening, apical fibrotic changes, or enlarged mediastinal
nodes were reported at lung CT scan.
Correlations between circulating monocyte/macrophage
phenotype, PFTs and sPAP values, in SSc patients
Higher percentages of circulating mixed M1/M2
monocyte/macrophage subset, characterized as
CD14+CD206+CD163+CD204+TLR4+CD80+CD86+
cells, showed a weak linear negative correlation with
DLCO% (p = 0.046, r = − 0.28, Fig. 3a).
No linear correlations were observed between macro-
phage subsets phenotype and FVC% values.
A FVC/DLCO ratio higher than 1.5 was associated
with several circulating monocyte/macrophage subset
percentages, and in particular: CD204+CD163+ cells cal-
culated over total CD204+ cells (FVC/DLCO< 1.5 = 9 ±
15% vs. FVC/DLCO> 1.5 = 13 ± 14%, p = 0.006), CD204+
CD163+TLR4+ cells calculated over CD204+ cells (FVC/
DLCO< 1.5 = 3 ± 15% vs. FVC/DLCO> 1.5 = 6.4 ± 15%, p
= 0.025), CD204+CD163+TLR4+ cells calculated over
total leucocytes (FVC/DLCO< 1.5 = 0.02 ± 0.25%, vs.
FVC/DLCO> 1.5 = 0.04 ± 0.02%, p = 0.039), CD204+
CD163+CD206+TLR4+CD86+ cells calculated over total
leucocytes (FVC/DLCO< 1.5 = 0.008 ± 0.03 vs. FVC/
DLCO> 1.5 = 0.04 ± 0.09% %, p = 0.041, Fig. 3b). As
regards cell subsets calculated over total CD14+ cells,
significant differences were observed with an FVC/
DLCO ratio lower or higher than 1.5: CD14+CD163+
cells (FVC/DLCO< 1.5 = 5.8 ± 2.4% vs. FVC/DLCO> 1.5
Table 2 The CD204 positive cell population percentages are shown in patients with (SSc-ILD) or without interstitial lung disease
(SSc-No ILD) at lung CT scan and healthy subjects (HSs)
Analysis of circulating CD204+ cells SSc-ILD (37) SSc-No-ILD (18) p (MW) HSs (27) p (KW)
CD204+ (%) 0.5 ± 0.40 0.8 ± 0.7 p = 0.13 0.7 ± 0.3 0.21
CD204+CD163+ (%leukocytes) 0.08 ± 0.22 0.09 ± 0.14 p = 0.65 0.03 ± 0.03 0.001
CD204+CD163+ (%CD204+) 13.7 ± 15 8.4 ± 13 p = 0.034 6.3 ± 3 < 0.0001
CD204+CD163+TLR4+ (%leukocytes) 0.03 ± 0.22 0.02 ± 0.15 p = 0.34 0.008 ± 0.01 < 0.0001
CD204+CD163+TLR4+ (%CD204+) 6.2 ± 16 2.9 ± 15 p = 0.025 1.4 ± 1.7 < 0.0001
CD204+CD163+CD206+ (%leukocytes) 0.01 ± 0.1 0.01 ± 0.05 p = 0.65 0.008 ± 0.01 0.001
CD204+CD163+CD206+ (%CD204+) 4 ± 7.4 1.9 ± 5.6 p = 0.07 1.1 ± 1.2 < 0.0001
CD204+CD163+CD206+TLR4+ (%leukocytes) 0.014 ± 0.1 0.11 ± 0.05 p = 0.20 0.003 ± 0.004 < 0.0001
CD204+CD163+CD206+TLR4+ (%CD204+) 2.7 ± 7.3 1.1 ± 5.9 p = 0.013 0.5 ± 0.6 < 0.0001
CD204+CD163+CD206+ TLR4+CD14+(%leukocytes) 0.003 ± 0.014 0.004 ± 0.003 p = 0.795 0.001 ± 0.003 0.008
CD204+CD163+CD206+ TLR4+CD14+(%CD204+) 0.73 ± 1.4 0.27 ± 0.54 p = 0.097 0.20 ± 0.38 < 0.0001
CD204+CD163+CD206+ TLR4+CD14− (%leukocytes) 0.009 ± 0.08 0.006 ± 0.05 p = 0.092 0.001 ± 0.002 < 0.0001
CD204+CD163+CD206+ TLR4+CD14− (%CD204+) 1.93 ± 6.56 0.6 ± 5.69 p = 0.029 0.17 ± 0.41 < 0.0001
CD204+CD163+CD206+ TLR4+CD80+ (%leukocytes) 0.01 ± 0.09 0.004 ± 0.05 p = 0.041 0.001 ± 0.003 < 0.0001
CD204+CD163+CD206+ TLR4+CD80+ (%CD204+) 2.07 ± 6.83 0.5 ± 5.33 p = 0.010 0.16 ± 0.48 < 0.0001
CD204+CD163+CD206+ TLR4+CD86+ (%leukocytes) 0.008 ± 0.08 0.005 ± 0.04 p = 0.082 0.001 ± 0.002 < 0.0001
CD204+CD163+CD206+TLR4+ CD86+ (%CD204+) 1.16 ± 5.8 0.72 ± 4.1 p = 0.023 0.19 ± 0.36 < 0.0001
CD204+CD163+CD206+TLR4+ CD80+CD86+ (%leukocytes) 0.04 ± 0.08 0.002 ± 0.03 p = 0.036 0.0006 ± 0.001 < 0.0001
CD204+CD163+CD206+TLR4+ CD80+CD86+ (%CD204+) 1 ± 5.6 0.39 ± 4 p = 0.021 0.08 ± 0.2 < 0.0001
By Mann-Whitney test, several mixed M1/M2 cell populations were found to show significantly higher percentages (p MW highlighted in bold) in SSc patients
affected by ILD, compared to SSc patients with no ILD. On the right, Kruskal-Wallis test was performed adding HSs data, obtaining more significant results (p KW)
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= 6.9 ± 2.3%, p = 0.044), CD14+CD206+ cells (FVC/
DLCO< 1.5 = 6.1 ± 2.8% vs. FVC/DLCO> 1.5 = 7.2 ± 2.8%,
p = 0.05), CD14+CD206+CD163+ cells (FVC/DLCO< 1.5
= 5.9 ± 2.7% vs. FVC/DLCO> 1.5 = 6.8 ± 2.7%, p = 0.046),
CD14+CD206+CD163+CD86+ cells (FVC/DLCO< 1.5 =
0.01 ± 0.022% vs. FVC/DLCO> 1.5 = 0.03 ± 0.03%, p =
0.034, Fig. 3c), and CD14+CD206+CD163+CD204+
TLR4+CD80+CD86+ cells (FVC/DLCO< 1.5 = 0.0001 ±
0.0005% vs. FVC/DLCO> 1.5 = 0.001 ± 0.005%; p = 0.005,
Fig. 3d, Additional file 3). Moreover, the higher percent-
age of mixed M1/M2 CD14+CD206+CD163+CD204+
TLR4+CD80+CD86+ cell subset correlated positively
with the sPAP value (p = 0.028, r = 0.29, Fig. 3e).
Discussion
The results of the present study demonstrated that a
population of circulating cells belonging to the monocyte/
macrophage lineage and expressing surface markers of
both M1 and M2 phenotypes exists, in significantly high
percentages, in SSc patients diagnosed as affected by ILD
at CT scan. Additionally, higher percentages of mixed
M1/M2 circulating monocytes/macrophages resulted
linearly correlated with lower values of DLCO%, with an
FVC/DLCO ratio higher then 1.5, and with higher PAPs
values. Finally, mixed M1/M2 cell populations demon-
strated to be associated with positivity for Scl-70 antibody,
a well-known predictor for lung function decline, and less
strictly with diffused disease form [29, 30].
Of note, among the circulating leucocyte population,
two initial gating strategies moving from CD204+ cells
and CD14+ cells gave significant results in patients af-
fected by SSc-related ILD. On the contrary, no significant
results were obtained when investigating CD80+CD86+
cells as initial gating strategy, thus confirming previous
studies demonstrating a prevalent presence of markers
characteristically linked with the alternately activated
macrophage phenotype in SSc patients [31, 32].
The cellular subsets that appear to be correlated with
pulmonary involvement seem to be essentially two: the
first characterized by the positivity for CD204 and other
M2 and M1 surface markers but negative for CD14; the
second subset made up of cells positive for CD14 and
for other M1 and M2 surface markers, possibly less ma-
ture than those positive for CD204. As described by
Fig. 2 ILD affected SSc patients: associations with mixed M1 M2 cells percentage. a and b, representative dot plots from the flow cytometry
analysis of the CD204 + CD163 + CD206 + TLR4 + CD80 + CD86+ cell subset in SSc patients affected by ILD and not affected by ILD are shown.
Mixed M1/M2 cells expressing CD80 and CD86 markers, among CD204+CD163+TLR4+CD206+ cells, resulted significantly increased in percentage
in the SSc-ILD group compared to the SSc-No ILD group, if calculated both over total CD204+ cells (c) and over total circulating leukocytes (d)
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Lambert et al., although the mature circulating mono-
cytes are classically characterized by their expression of
CD14, this marker seems not to be considered the hall-
mark for monocyte identification, in particular in the
late phase of maturation, which is accompanied by the
expression of CD16 [27]. Moreover, the CD14lowCD16+
monocyte subset seems to correspond to M2 mono-
cytes/macrophages. Interestingly, in a recent study by
Lescoat et al., CD16+ monocytes resulted not only asso-
ciated with pulmonary fibrosis, severity of the restrictive
disease and reduction of DLCO but also they were de-
scribed as precursors of M2 macrophages [33]. Accord-
ingly, even if CD16 was not evaluated in our present
study, it may be possible to speculate that the mixed
M1/M2 population derived from CD204+ monocytes,
which is CD14− and associated with ILD, might be posi-
tive for CD16.
The presented findings could open to the perspective
of a possible role of mixed M1/M2 cells in SSc and
SSc-associated ILD pathogenesis, or at least as potential
biomarkers for lung involvement in SSc. In a recent
study, an integrated genomic approach using a consen-
sus clustering was performed to compare the gene ex-
pression profiles of SSc biopsies from different tissues,
including skin, lung and peripheral blood mononuclear
cells. The authors described the concept of the
immune-fibrotic axis, that is a common pathogenic gene
expression signature indicative of the fundamental role
of macrophages [34].
In particular, a distinct macrophage signature associ-
ated with the alternative activation was observed in
SSc-associated pulmonary fibrosis and in the skin of pa-
tients with an “inflammatory” SSc gene expression signa-
ture, suggesting that there are subtle differences in the
macrophage gene expression in lung and skin [34].
Based on these observations, the authors concluded that
the plasticity of the monocyte/macrophage lineage is
likely to be central to the divergence of fibrotic processes
in different SSc-affected tissues and is an important
component of an immune-fibrotic axis driving disease
pathogenesis [34].
At the same time, the statistics from the present study
show the constant presence, in patients affected or not
by ILD, of a great variability of cell percentages obtained
from the analysis of the various circulating monocyte/
macrophages subsets, testified by large standard devia-
tions, and reflecting considerable heterogeneity in cell
size. Although this phenomenon could be attributed to
Fig. 3 DLCO%, FVC/DLCO, sPAP values associations with mixed M1 M2 phenotype cells percentages. a a linear correlation between the
mixed M1/M2 phenotype subset CD14+CD206+CD163+CD204+TLR4+CD80+CD86+ cell percentages and DLCO% values is shown. b an FVC/
DLCO ratio higher than 1.5 resulted associated with CD204+CD163+CD206+TLR4+CD86+ cell subset percentage. c an FVC/DLCO ratio
higher than 1.5 resulted associated with CD14+CD206+CD163+CD86+ cell subset percentage. d an FVC/DLCO ratio higher than 1.5
resulted associated with CD14+CD206+CD163+CD204+TLR4+CD80+CD86+ cell subset. e a linear correlation between the mixed M1/M2
phenotype subset CD14+CD206+CD163+CD204+TLR4+CD80+CD86+ cell percentages and sPAP values is shown
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the limited sample size, it may also be related to the cells
phenotype plasticity in relation with different environ-
mental stimuli and to their capacity to rapidly change
accordingly, resulting in wide distribution of surface
markers positivity at the time of the analysis [20].
Several authors have focused on how macrophage
phenotype modifications could contribute to the develop-
ment of lung fibrotic and neoplastic disorders [14, 16].
However, the studies often concentrated on the expression
of single phenotype surface markers or soluble molecules
and their possible association with diseases clinical fea-
tures. It is the case, for example, of the presence of the
M2 markers CD163 or soluble (s)CD163 that showed to
be higher in presence of several organ involvements, like
in ILD and pulmonary arterial hypertension (PAH), in SSc
and other autoimmune diseases, like polymyositis and
dermatomyositis [28, 29].
Serum and urinary sCD163 concentrations were very
recently investigated as possible biomarkers in SSc pa-
tients compared to HSs and a study demonstrated that
serum sCD163 levels were significantly higher in SSc pa-
tients compared to HSs [35]. However, sCD163 concen-
trations were not associated with clinical, laboratory,
and instrumental characteristics of SSc patients [35].
Other authors described M2 macrophages in SSc pa-
tients and their association with several clinical parame-
ters. Higher percentages of circulating cells positive for
CD204, CD163, and CD14 were shown to correlate with
skin involvement [31].
Circulating alternatively activated CD14+ macro-
phages, expressing high levels of CD206 were demon-
strated to be associated with PAH [32].
A recent study investigated the phenotype of human
alveolar macrophages (AMs) in adults living in UK and
Malawi, demonstrating that the majority of AMs
expressed high levels of M1 and M2 markers simultan-
eously. As the authors postulate, it is possible that in the
healthy lung mucosa, combined M1/M2 features could
confer to AMs the ability of maintaining a balance be-
tween immune tolerance and protective immunity. On
the contrary, a similar circulating phenotype could exert
a pathogenic role in SSc patients [21].
Moreover, it was demonstrated that monocyte-derived
macrophages co-expressing CD206, CD163 and CD169
were significantly higher in SSc-ILD than in lung cancer
or sarcoidosis and that a similar macrophage phenotype
was obtained from the analysis of blood-monocytes de-
rived macrophages in SSc patients [36].
However, to our knowledge, no one has so far attempted
such a wide phenotype characterization of circulating
monocytes/macrophages in connection with the develop-
ment of SSc-related lung and right heart complications.
This study has several limits. First of all, the relatively
small patient population. In fact, even if in a previous
paper an effect of treatment regimens on circulating
monocyte/macrophage phenotype was observed [22], in
the present study a further subgroup analysis of patients
with lung involvement and undergoing specific treatments
compared to non-treated patients, seems not to be pos-
sible without losing too much statistical power. A follow
study including a larger number of SSc patients is
planned. Accidentally, most of the patients in the study
population had consistently high levels of FVC (average
values 104%) and very few patients had a severe restrictive
disease, therefore it was not possible to ascertain the pres-
ence of a linear correlation with FVC% or with its decline.
Secondarily, the evaluation of only circulating cells is
also a limitation. In fact, while interpreting the presented
results, it should be kept in mind that a wide debate is
taking place on the possible link between circulating and
tissue resident monocyte/macrophage cells, questioning
the dogma on the monocyte origin of tissue macro-
phages. Infiltrating macrophages, observed in the dis-
eased tissue, seem to derive from circulating monocytes,
but several studies opposed the monocyte origin for tis-
sue resident cells [37, 38].
Moreover, emerging immunological theories attri-
bute to organ and tissues the control of immune sys-
tem activation and its forms (Th1 or Th2 like) [39].
Although the surface markers investigated in the
study (primarily CD204, CD163 and CD206) are con-
sidered specific for the characterization of M2 polar-
ized cells, they can also be expressed by dendritic
cells [40, 41]. Therefore, based on the gating strat-
egies proposed in our study, a percentage of dendritic
cells might be present in the described circulating cell
subsets. Monocytes, macrophages and dendritic cells
are all members of the mononuclear phagocyte sys-
tem which is involved in multiple functions during
immune responses and, although these cells may be
distinguished based on functional and phenotypical
characteristics, some cell features are often overlap-
ping and the distinction or classification is challen-
ging [42]. The possible implication of dendritic cells
in the development of SSc was recently highlighted in
a recent paper by Silvan et al. describing that these
cells expressing high levels of PSGL-1 were associated
with the presence of interstitial lung disease in SSc
patients [43].
Finally, the very low percentage of the newly de-
scribed circulating cells could make it not easy to use
them as a disease biomarker. Evidently, further and
larger studies and possibly the sorting of the mixed
M1/M2 population will be useful for the evaluation of
the importance of this phenotype in both pathogenic,
diagnostic or therapeutic perspectives.
Although the identification of these circulating
mixed M1/M2 cells was performed through the
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evaluation of the most investigated and specific
markers related to each polarization status and in a
previous study they were found significantly increased
in SSc patients compared to HSs, the analysis of the
marker expression through the detection of the mean
fluorescence intensity (MFI), not investigated in this
study, might represent a further important aspect that
may contribute to understand their possible role in
SSc pathogenesis.
In accordance with our results on a possible circulat-
ing “scleroderma” macrophage with M1/M2 phenotype,
very recently, Moreno-Moral et al. have found in 57 SSc
patients, through RNA sequencing and genome-wide
genotyping, a mixed macrophage activation signature,
characterized by the downregulation of interferon
gamma response, attesting for an M2 polarization, but
also by the downregulation of the interleukin (IL)-6/
JAK/STAT3 signalling pathway, suggesting for a re-
stricted M2 activity [44]. The authors observe that the
circulating monocyte/macrophage phenotype could con-
trast with macrophage signature in tissues such as lung,
in which a STAT3-dependent expression of CD163 was
associated with pulmonary fibrosis [45].
Interstitial lung disease is a major cause of morbidity
and mortality in systemic sclerosis (SSc). Notwithstanding
many authors concentrated their attention in this direc-
tion, the pathogenic mechanisms of SSc-related ILD re-
main unknown, and limited therapeutic effects are
obtained with the available treatments [46–48].
The knowledge of the mechanisms that initiate the patho-
genesis of pulmonary damage or of an easily evaluable bio-
marker associated with such involvement would be crucial.
Supported by the discovery of interferon (IFN) α,
tumor necrosis factor (TNF) α, TLRs, transforming
growth factor (TGF) β, platelet derived growth factor
(PDGF), genes signatures in SSc, we hypothesized that
both Th1 and Th2 activation signals could derive from
different damaged tissues, determining the development
of circulating mixed M1/M2 cells. At the same time,
more polarized responses could possibly develop at tis-
sues level, such as in lungs [39].
Conclusions
In conclusion, it is possible to state that this is the first
study showing an association of an M1/M2 monocyte/
macrophage phenotype in SSc patients to SSc-related
ILD functional and radiological data.
The evaluation of the existence of circulating mixed
M1/M2 monocyte/macrophage phenotype and its clin-
ical associations in SSc patients, should be considered as
the first step towards a conclusion for a possible role as
a pathogenic factor or as an early biomarker for organ
involvement in SSc-related ILD. Such a phenotype could
be found also in other pulmonary diseases, at the
circulatory or tissue level. The presented acquisitions
could therefore be considered as an opening to later
studies on a wide phenotype characterization of macro-
phages at the level of different diseased tissues including
lung, kidney, heart, and skin in SSc but also in other fi-
brotic disorders. Furthermore, isolation and functional
study of the described cells are under evaluation for the
remarkable values they could have for physiopathology,
diagnostic and therapeutic purposes [49].
Additional files
Additional file 1: Gating strategies for the detection of circulating M1,
M2 and mixed M1/M2 cells in systemic sclerosis patients and healthy
controls. (A) Representative flow cytometry scatter plot and scatter dot
plot with median and interquartile range of the initial gating strategy
starting from the circulating CD14+cells percentage (%) in the leucocyte
population; (B) Representative flow cytometry panels with quadrant
regions and scatter dot plot representation of the of circulating
CD14+CD206+CD163+cells in the CD14+cell population; (C)
CD14+CD206+CD163+CD204+TLR4+cells in the CD14+CD206+CD163+cell
subset and (D) CD14+CD206+CD163+CD204+TLR4+CD80+CD86+cells in
the CD14+CD206+CD163+TLR4+cell subset of healthy subjects (HSs) and
systemic sclerosis patients (SSc pts). (E) Representative flow cytometry
scatter plot and scatter dot plot with median and interquartile range of
the initial gating strategy starting from the circulating CD204+cells
percentage (%) in the leucocyte population; (F) Representative flow
cytometry panels with quadrant regions and scatter dot plot
representation of the of circulating CD204+CD163+CD206+cells in the
CD204+cell population; (G) CD204+CD163+CD206+TLR4+cells in the
CD204+CD163+CD206+cell subset; (H) CD204+CD163+CD206+TLR4+CD80
+CD86+cells and (I) CD14+ and CD14−cells in the CD204+ 163+CD206
+TLR4+cell subset of HSs and SSc pts. (J) Representative flow cytometry
scatter plot of the initial gating strategy starting from the circulating
CD80 + CD86 + cells percentage (%) in the leucocyte population and (L)
representative flow cytometry panels with quadrant regions of the of
circulating CD80+CD86+TLR2+TLR4+cells in the CD80+CD86+cell
population of HSs and SSc pts. Statistical analysis was performed by
Mann-Whitney non-parametric test and p-values lower than 0.05 was
considered as statistically significant. (TIF 1646 kb)
Additional file 2: Differences in the percentage of mixed M1/M2 cells in
systemic sclerosis patients with or without Ab anti Scl70 positivity and
healthy subjects. Cell populations with a mixed M1/M2 phenotype,
showing significantly different percentages between Scl70 antibody
positive (Scl70 + Pts) and Scl70 antibody negative (Scl70-Pts) patients at
Mann-Whitney were then analyzed together with those from age and
gender matched healthy subjects (HSs) through Kruskal-Wallis test. HSs
showed constantly lower percentages compared to Scl70 + Pts and
Scl70-Pts. (TIF 514 kb)
Additional file 3: Differences in the percentage of M2 and mixed M1/
M2 cells in systemic sclerosis patients with an FVC/DLCO ratio lower or
higher than 1.5. With both gating strategies, one based on CD204
positivity and one based on CD14 positivity, cell populations with an M2
or a mixed M1/M2 phenotype, showed significantly higher percentages
in patients with an FVC/DLCO ratio higher then 1.5 compared to patients
with an FVC/DLCO ratio lower than 1.5. (DOCX 13 kb)
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Ab anti-Scl70: anti-topoisomerase antibody; ACA: Anti-centromere antibodies;
ACR: American College of Rheumatology; ANA: Anti-nuclear antibody;
CT: Computed tomography;; dcSSc: Diffused cutaneous systemic sclerosis;
DLCO: Diffusing capacity of the lungs for carbon monoxide;
EULAR: European League Against Rheumatism; FVC: Forced vital capacity;
IL: Interleukin; ILD: Interstitial lung disease; lcSSc: Limited cutaneous systemic
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specific interstitial pneumonia; PFTs: Pulmonary function tests; pro-BNP: Pro-
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phenomenon; SD: Standard deviation; sPAP: Systolic pulmonary artery
pressure; SSc: Systemic sclerosis; Th: T helper; TLR: Toll-like receptors
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